Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Return on Capital Employed (2016 - 2025)

Sangamo Therapeutics (SGMO) has 14 years of Return on Capital Employed data on record, last reported at 2.54% in Q3 2025.

  • For Q3 2025, Return on Capital Employed fell 16.0% year-over-year to 2.54%; the TTM value through Sep 2025 reached 2.54%, down 16.0%, while the annual FY2024 figure was 1.19%, 32.0% down from the prior year.
  • Return on Capital Employed reached 2.54% in Q3 2025 per SGMO's latest filing, down from 1.42% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.17% in Q1 2021 and bottomed at 3.57% in Q2 2024.
  • Average Return on Capital Employed over 5 years is 1.22%, with a median of 0.66% recorded in 2023.
  • Peak YoY movement for Return on Capital Employed: plummeted -292bps in 2024, then soared 215bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.3% in 2021, then crashed by -46bps to 0.43% in 2022, then tumbled by -339bps to 1.89% in 2023, then grew by 9bps to 1.71% in 2024, then tumbled by -48bps to 2.54% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 2.54% in Q3 2025, 1.42% in Q2 2025, and 1.85% in Q1 2025.